JAMA Oncol 2019 Sep 29
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Related Questions
In which situations would you consider this a reasonable treatment option?
New answer by Medical Oncologist at Mayo Clinic (October 6, 2021)
Whereas ER 1-9% represents a heterogeneous group of tumors with relatively poor response to endocrine monotherapy, there are few if any data on whether this group of patients ...